In hypertension management, examining the role of newer agents including aldosterone synthase inhibitors and injectable angiotensinogen inhibitors which are on the horizon and how the diffusion of such therapies may influence AF-related stroke and mortality is needed[193,194]. The gene discussed is CYP11B2; the disease is hypertensive disorder.